Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Alzheimer'S & Dementia (Amsterdam, Netherlands)|February 5, 2026
Interchangeability of blood-based biomarkers and PET to identify Alzheimer's disease pathologyJian Wang, Joel B Braunstein, Robin Wolz, et al.
Journal of Alzheimer'S Disease : JAD|September 25, 2015
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer's DiseaseHong Liu-Seifert, Eric Siemers, Karen Price, et al.
Alcoholism, Clinical and Experimental Research|July 21, 2016
Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol DependenceAnke Post, Trevor S Smart, Kimberley Jackson, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 13, 2024
The case for regulatory approval of amyloid-lowering immunotherapies in Alzheimer's disease based on clearcut biomarker evidencePaul Aisen, Randall J Bateman, Damian Crowther, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 30, 2009
Scales as outcome measures for Alzheimer's diseaseRonald Black, Barry Greenberg, J Michael Ryan, et al.
Alzheimer'S Research & Therapy|June 12, 2015
Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer's diseaseRachelle S Doody, Rema Raman, Reisa A Sperling, et al.
The New England Journal of Medicine|January 24, 2014
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's diseaseRachelle S Doody, Ronald G Thomas, Martin Farlow, et al.
Schizophrenia Research|November 18, 2008
Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of functionLeah Kleinman, Jeffrey Lieberman, Sanjay Dube, et al.
The New England Journal of Medicine|July 26, 2013
A phase 3 trial of semagacestat for treatment of Alzheimer's diseaseRachelle S Doody, Rema Raman, Martin Farlow, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|July 3, 2019
Erratum: A Selective Nociceptin Receptor Antagonist to Treat Depression: Evidence from Preclinical and Clinical StudiesAnke Post, Trevor S Smart, Judith Krikke-Workel, et al.
Pageof 3